Lung Cancer Clinical Trial

Lung EpiCheck Biomarkers Development Study

Summary

This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.

View Full Description

Full Description

This is a prospective, multi-center, observational nonsignificant risk study aimed to collect blood and clinical data from primary lung cancer and control subjects to characterize various biomarkers that will discriminate between lung cancer and control subjects.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria - Cases:

Age 50-80 years
Subjects who are currently smoking or former smokers, with at least 20 pack-years
Subjects with either A high suspicion for lung cancer, with planned biopsy or surgery to establish a definitive diagnosis within 60 days after enrollment or treatment naive lung cancer patients confirmed by pathology.

Exclusion Criteria - Cases

Known diagnosis or treatment of cancer from any kind in the past 5 years, except of fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix and except from the current lung cancer

Inclusion Criteria - USPSTF risk

Age 50-80 years
Subjects who are currently smoking or former smokers, with at least 20 pack-years

Exclusion Criteria - USPSTF risk

- Known diagnosis or treatment of cancer of any kind in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix

Inclusion Criteria - Healthy controls

Age 20-80 years
Never smoker or current / previous smoker < 20 pack year history

Exclusion Criteria - Healthy Controls

Known diagnosis or treatment of cancer of any kind in the past (lifetime), except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix.
Not previously diagnosed with a lung lesion highly suspicious for cancer
Under follow up or work up for any lesion suspicious for any type of cancer
Presenting with fever with body temperature 100.4°F (38°C) or higher
Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw
Pregnancy
Any history of blood product transfusion within 30 days prior to blood draw

Study is for people with:

Lung Cancer

Estimated Enrollment:

6000

Study ID:

NCT06245876

Recruitment Status:

Recruiting

Sponsor:

Nucleix Ltd.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Life Spring Clinical Research
Miami Florida, 33130, United States
Emerald Coast OBGYN
Panama City Florida, 32405, United States
Ochsner LSU Health Shreveport - Regional Urology
Shreveport Louisiana, 71106, United States
Comprehensive Urology
Southfield Michigan, 48076, United States
Michigan Institute of Urology, P.C.
Troy Michigan, 48084, United States
Urology San Antonio
San Antonio Texas, 78229, United States
National Koranyi Institute for Pulmonology
Budapest , , Hungary
Carmel Medical Center
Haifa , , Israel
Sourasky Medical Center
Tel Aviv , , Israel
ZGT Medical Center
Hengelo , , Netherlands

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

6000

Study ID:

NCT06245876

Recruitment Status:

Recruiting

Sponsor:


Nucleix Ltd.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider